IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1669
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$5.2B
Christian Behrenbruch
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our company was incorporated under the laws of Australia in January 2017. Our headquarters and registered offices are located at 55 Flemington Road, North Melbourne, Victoria, 3051, Australia. Our agent for service of process in the United States is Telix Pharmaceuticals (US) Inc., located at 11700 Exit 5 Pkwy, Suite 200, Fishers, Indiana.
Headcount
—
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = TLX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TLX Telix Pharmaceuticals Ltd | 52 | 77 | 57 | 13 | 167.0x | 11.2x | 76.4% | 27.3% | 65.1% | 10.5% | 6.4% | 51.7% | 0.0% | 107.0x | $5.2B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Telix Pharmaceuticals Ltd (TLX) receives a "Hold" rating with a composite score of 52.1/100. It ranks #1669 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
NORTH MELBOURNE,
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for TLX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 77 | 88 | -11DRAG |
| MOMENTUM | 13 | 5 | +8ALPHA |
| VALUATION | 57 | 48 | +9ALPHA |
| INVESTMENT | 26 | 26 | 0NEUTRAL |
| STABILITY | 48 | 40 | +8ALPHA |
| SHORT INT | 86 | 95 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 76.4% (sector -1.9%)
GM 65% vs sector 44%, OM 10% vs sector 3%
Capital turnover N/A, R&D intensity 24.2%
Rev growth 52%
Interest coverage 1.7x, Net debt/EBITDA -1.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Telix Pharmaceuticals Ltd (TLX) as a Hold with a composite score of 52.1/100 at a current price of $6.65. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Telix Pharmaceuticals Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.1/100 places it at rank #1669 in our full universe.
Narrow
High
Standard
Fair Value
Gross margins of 65% signal strong pricing power.
Returns on equity of 76.4% exceed cost of capital.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 167.0x leaves little room for execution misses.
Leverage of 107% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Telix Pharmaceuticals Ltd represents a hold based on multi-factor quantitative performance.
Our model assigns Telix Pharmaceuticals Ltd a Hold rating, with a composite score of 52.1/100 and 3 out of 5 stars. Ranked #1669 of 7,333 stocks, TLX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
TLX earns a quality score of 77/100, indicating above-average business quality. The company reports a return on equity of 76.4% (sector avg: -1.9%), gross margins of 65.1% (sector avg: 44.1%), net margins of 6.4% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
TLX's value score of 57/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 166.96x, an EV/EBITDA of 11.16x, a P/B ratio of 7.67x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
Telix Pharmaceuticals Ltd's investment score of 26/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 51.7% vs. a sector average of 6.7% and a return on assets of 27.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Telix Pharmaceuticals Ltd is experiencing notably weak momentum with a score of just 13/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 51.7% year-over-year, while a beta of 1.95 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 48/100, TLX exhibits average financial resilience. Key stability metrics include a beta of 1.95 and a debt-to-equity ratio of 107.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
TLX's short interest factor score of 86/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include high market sensitivity (beta: 1.95), elevated leverage (D/E: 107.00x). As a mid-cap company with a market capitalization of $5.2B, Telix Pharmaceuticals Ltd benefits from the generally lower volatility and deeper liquidity associated with its size class.
Telix Pharmaceuticals Ltd is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1669 of 7,333 overall (77th percentile). Key comparisons include ROE of 76.4% exceeding the -1.9% sector median and operating margins of 10.5% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TLX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Short Int. (86) vs Momentum (13) — closing this gap could shift the rating.
EV/EBITDA IN LINE WITH SECTOR BENCHMARKS
ROE 4121% BELOW SECTOR MEDIAN
Gross Margin 48% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
The global medical cyclotron market shows steady growth, expected to be valued at around US$246.8 million in 2026 and projected to reach US$405.4 million by 2033, with a CAGR of 5.4% during this period. This growth stems from expanding adoption of PET imaging, increased investments in nuclear medicine, and continuous innovation in compact and higher-energy cyclotron technologies that enhance isotope yield and operational efficiency.
These ASX 200 growth shares have catalysts that I think could help them outperform the broader market.
Earlier this week, Telix Pharmaceuticals reported full-year 2025 sales of US$803.79 million with a small net loss, issued 2026 revenue guidance of US$950–970 million, filed a U.S. shelf registration for its American Depositary Shares, and submitted a European marketing authorization application for its glioma imaging agent TLX101-Px. Taken together, stronger product revenues, added financing flexibility via the shelf registration, and advancing a brain cancer imaging candidate underscore how...
CSL shares are going through a rough patch. Brokers see modest upside for CSL, while they are very bullish on rival Telix Pharmaceuticals.
Major players made the list of most-traded ASX shares last week.